Detail of the clinical trial
| Title of the trial | Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical |
|---|---|
| EudraCT number | 2016-002347-41 |
| Protocol number | CA209-744 |
| Sponsor | Bristol-Myers Squibb International Corporation, Chaussée de la Hulpe 185, 1170 Brussels, Belgium |
| Indications | Hemato-oncology |
| Diagnosis | Hodgkin lymphoma |
| Population in clinical trial |
Children (2-11 years) Adolescents (12-17 years) Adults (18-65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2017 |
| Date of approval by Institute (SÚKL) | 8.3.2017 |
| Date of approval by EC | |
| Date of initiation CT in ČR | |
| Date of ending CT in ČR | 6.1.2020 |
| Notice | |
| Sites | Fakultní nemocnice v Motole,Klinika dětské hematologie a onkologie,V Úvalu 84,Praha 5,150 06 |
cz